Prognostic Impact of the Turin Criteria in Poorly Differentiated Thyroid Carcinoma.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
pubmed:
18
5
2019
medline:
1
1
2020
entrez:
18
5
2019
Statut:
ppublish
Résumé
The Turin criteria including solid, trabecular, and/or insular architecture, lack of typical nuclear features of papillary carcinoma, and mitoses, necrosis, or convoluted nuclei were adopted in the recent 4th edition of the World Health Organization classification published in 2017. Between 2006 and 2017, 11,001 cases underwent initial surgery for primary malignant thyroid tumor derived from follicular cells. A total of 75 (0.7%) cases were diagnosed with PDTC according to the 2004 WHO classification. Based on the Turin criteria, 30 (40%) cases were re-classified as PDTC-Turin (+) and 45 (60%) cases were PDTC-Turin (-). Clinicopathological features and prognosis were compared between PDTC-Turin (+) and PDTC-Turin (-). Seventy-five patients (48 females and 27 males) had a median age at the time of surgery of 57 years. Preoperative diagnosis was benign in 16 (21%), follicular tumor in 40 (53%), and malignant in 19 (25%). The 5-year cause-specific survival (CSS) and disease-free survival (DFS) rates were 97% and 44% for PDTC-Turin (+) and 100% and 88% for PDTC-Turin (-). On univariate analysis, CSS and DFS rates were significantly worse in the PDTC-Turin (+) than in the PDTC-Turin (-) (p = 0.0096, and p = 0.0016). Multivariate analysis showed that Turin criteria status, Ki-67 labeling index ≥ 10%, and age 55 ≥ years were the independent prognostic factors for recurrence. The prevalence of PDTC diagnosed with the Turin criteria was low, but it showed more aggressive behavior. The 2017 WHO classification reflects the prognosis more accurately than the 2004 WHO classification.
Sections du résumé
BACKGROUND
The Turin criteria including solid, trabecular, and/or insular architecture, lack of typical nuclear features of papillary carcinoma, and mitoses, necrosis, or convoluted nuclei were adopted in the recent 4th edition of the World Health Organization classification published in 2017.
MATERIALS AND METHODS
Between 2006 and 2017, 11,001 cases underwent initial surgery for primary malignant thyroid tumor derived from follicular cells. A total of 75 (0.7%) cases were diagnosed with PDTC according to the 2004 WHO classification. Based on the Turin criteria, 30 (40%) cases were re-classified as PDTC-Turin (+) and 45 (60%) cases were PDTC-Turin (-). Clinicopathological features and prognosis were compared between PDTC-Turin (+) and PDTC-Turin (-).
RESULTS
Seventy-five patients (48 females and 27 males) had a median age at the time of surgery of 57 years. Preoperative diagnosis was benign in 16 (21%), follicular tumor in 40 (53%), and malignant in 19 (25%). The 5-year cause-specific survival (CSS) and disease-free survival (DFS) rates were 97% and 44% for PDTC-Turin (+) and 100% and 88% for PDTC-Turin (-). On univariate analysis, CSS and DFS rates were significantly worse in the PDTC-Turin (+) than in the PDTC-Turin (-) (p = 0.0096, and p = 0.0016). Multivariate analysis showed that Turin criteria status, Ki-67 labeling index ≥ 10%, and age 55 ≥ years were the independent prognostic factors for recurrence.
CONCLUSIONS
The prevalence of PDTC diagnosed with the Turin criteria was low, but it showed more aggressive behavior. The 2017 WHO classification reflects the prognosis more accurately than the 2004 WHO classification.
Identifiants
pubmed: 31098668
doi: 10.1007/s00268-019-05028-5
pii: 10.1007/s00268-019-05028-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2235-2244Références
Surgery. 1988 Dec;104(6):963-70
pubmed: 3194848
J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404
pubmed: 14602780
J Clin Invest. 2016 Mar 1;126(3):1052-66
pubmed: 26878173
Cancer. 2006 Mar 15;106(6):1286-95
pubmed: 16470605
Histopathology. 2012 Jun;60(7):1045-51
pubmed: 22348590
Am J Surg Pathol. 2011 Dec;35(12):1866-72
pubmed: 21989341
Hum Pathol. 1995 Feb;26(2):139-46
pubmed: 7860043
Lancet. 2014 Jul 26;384(9940):319-28
pubmed: 24768112
J Surg Oncol. 2004 Apr 1;86(1):44-54
pubmed: 15048680
Am J Clin Pathol. 2009 Nov;132(5):658-65
pubmed: 19846805
Clin Endocrinol (Oxf). 2008 Apr;68(4):618-34
pubmed: 18070147
World J Surg. 2008 Jul;32(7):1535-43; discussion 1544-5
pubmed: 18224467
Chin Med J (Engl). 2016 Jan 20;129(2):169-73
pubmed: 26830987
J Clin Endocrinol Metab. 2009 Dec;94(12):4735-41
pubmed: 19837916
Am J Surg Pathol. 1999 Jun;23(6):678-85
pubmed: 10366150
Nat Rev Cancer. 2006 Apr;6(4):292-306
pubmed: 16557281
Endocr Relat Cancer. 2013 Jul 12;20(4):603-10
pubmed: 23766237
Histopathology. 2014 Jan;64(2):263-73
pubmed: 24164362
World J Surg. 2010 Jun;34(6):1265-73
pubmed: 19953247
Mod Pathol. 2010 Sep;23(9):1269-78
pubmed: 20562850
J Clin Endocrinol Metab. 2014 May;99(5):E754-65
pubmed: 24476079
Cancer. 1983 Nov 15;52(10):1849-55
pubmed: 6313176
J Clin Endocrinol Metab. 2014 Apr;99(4):1245-52
pubmed: 24512493
Endocr J. 2018 Jun 27;65(6):621-627
pubmed: 29618671
Am J Surg Pathol. 1984 Sep;8(9):655-68
pubmed: 6476195
Cancer. 2004 Mar 1;100(5):950-7
pubmed: 14983490
N Engl J Med. 2015 Feb 12;372(7):621-30
pubmed: 25671254
J Clin Endocrinol Metab. 2013 Sep;98(9):E1562-6
pubmed: 23833040
Am J Pathol. 2001 Mar;158(3):987-96
pubmed: 11238046
Cancer Res. 2009 Jun 1;69(11):4885-93
pubmed: 19487299
Am J Surg Pathol. 2007 Aug;31(8):1256-64
pubmed: 17667551
Cancer. 2012 Jul 1;118(13):3260-7
pubmed: 22252610
Endocr J. 2013;60(3):375-82
pubmed: 23197046
Mod Pathol. 2017 Nov;30(11):1527-1537
pubmed: 28731042
J Ultrasound Med. 2016 Sep;35(9):1873-9
pubmed: 27388812
Endocr J. 2015;62(1):1-12
pubmed: 25195708
World J Surg. 2007 Jul;31(7):1417-24
pubmed: 17534542